首页/数据集/Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

NCATS Open Data2024-10-08 更新2026-08-08 收录

流感疫苗免疫原性

加强针研究

数据链接：

https://doi.org/10.1016/j.isci.2024.110728 数据链接链接失效反馈

官方服务：

资源简介：

Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

应用场景：

创建时间：

2024-09-20

流感疫苗免疫原性

年龄相关免疫应答差异

Seasonal influenza vaccines are available in multiple formulations including egg-based inactivated standard-dose, cell-based inactivated, recombinant, and live-attenuated. However, vaccine effectivene

NIAID Data Ecosystem100

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

流感疫苗免疫原性

疫苗临床试验

Randomized, double-blind, placebo-controlled clinical trial of Ad26.COV2.S on 25 participants. Participants were randomized to receive single-shot and 2-shot vaccine regimens with either 5 X 1010 or 1

DataCite Commons2022-12-21 更新60

Induction of Heterosubtypic Cross-Protection against Influenza by a Whole Inactivated Virus Vaccine: The Role of Viral Membrane Fusion Activity

疫苗交叉保护

流感疫苗免疫原性

BackgroundThe inability of seasonal influenza vaccines to effectively protect against infection with antigenically drifted viruses or newly emerging pandemic viruses underlines the need for developmen

NIAID Data Ecosystem40

Hemagglutination-Inhibition Titer

流感疫苗免疫原性

血凝抑制试验抗体滴度

aDose based upon HA contentbInfluenza viruses used in the HAI assay against sera collected at week 5.cHAI GMT plus or minus SEM.dVLP vs. rHA comparing same dose, t-test, *p

Figshare2015-12-02 更新70

DataSheet_3_Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial.pdf

COVID-19疫苗免疫评估

流感疫苗免疫原性

Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in parti

NIAID Data Ecosystem50

Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

资源简介：

相关数据集